Your session is about to expire
← Back to Search
Chemotherapy
Observational (movement assessment, medical data collection) for Breast Cancer
N/A
Waitlist Available
Led By Naoto T Ueno
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Summary
This study assesses the performance status in stage I-III triple negative breast cancer patients who are receiving neoadjuvant chemotherapy. Information collected in this study may help doctors learn if movement and fitness trackers can be used to predict side effects in cancer patients receiving chemotherapy.
Eligible Conditions
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Secondary outcome measures
Correlation between patient reported outcomes (PRO) data and movement tracker data
Trial Design
1Treatment groups
Experimental Treatment
Group I: Observational (movement assessment, medical data collection)Experimental Treatment2 Interventions
Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,039 Previous Clinical Trials
1,799,674 Total Patients Enrolled
148 Trials studying Breast Cancer
63,277 Patients Enrolled for Breast Cancer
Naoto T UenoPrincipal InvestigatorM.D. Anderson Cancer Center
8 Previous Clinical Trials
2,498 Total Patients Enrolled
Meghan Karuturi, MDPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
30 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger